Milestone Scientific adds pain medicine expert to board

Milestone Scientific Inc. (NYSE: MLSS) appointed Dr. Dawood Sayed to its board of directors, effective immediately, according to a company statement.

Dr. Sayed serves as Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center, where he is Division Chief of Pain Medicine, Director of Interventional Spine Services, and Director of the Center for Neuromodulation. He also holds the position of Vice Chairman and Co-Founder of the American Society of Pain and Neuroscience.

The appointment comes as Milestone Scientific seeks to expand adoption of its CompuFlo Epidural System in pain management and spine intervention markets. The system uses real-time pressure feedback to identify the epidural space during procedures.

"His deep expertise in pain medicine and strong relationships across the clinical and payer communities will be instrumental as we expand adoption of CompuFlo across pain management and spine intervention markets," stated Neal Goldman, Chairman of Milestone Scientific.

Dr. Sayed has authored over 100 peer-reviewed publications and received the 2025 Presidential Award from the North American Neuromodulation Society. He currently leads multiple clinical trials evaluating neuromodulation and spinal therapies.

The CompuFlo Epidural System was recently assigned a Medicare Part B payment rate under CPT code 0777T in several jurisdictions. The technology is designed as an alternative to traditional loss-of-resistance techniques used in epidural procedures.

"CompuFlo is a truly disruptive technology that addresses a long-standing challenge in spinal procedures," said Dr. Sayed. "I look forward to working with the team to drive greater clinical adoption and improve procedural safety."

Milestone Scientific develops computerized drug delivery instruments for medical and dental applications using its DPS Dynamic Pressure Sensing Technology platform.

You May Also Be Interested In

• Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
• Saba Capital funds reapprove merger plan targeting Q4 2026 close
• RenovoRx receives USPTO notice of allowance for RenovoCath patent